Compare Eli Lilly And Co (LLY) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs T-Mobile Us Inc — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while T-Mobile Us Inc trades at $148.75 (market cap $183.76B). The key difference: Eli Lilly And Co is far larger — about 5.7× T-Mobile Us Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and T-Mobile Us Inc for 84 Days on average.
| LLY | TMUS | |
|---|---|---|
Market Cap | $1.04T | $183.76B |
Volume | 3,064,878 | 4,294,650 |
Sector | Health | Media |
52-Week High | $1.28K | $230.06 |
52-Week Low | $799.57 | $161.73 |
Typical Hold Time | 93 Days | 84 Days |
Enterprise Value | $1.09T | $300.37B |
Dividend Yield | 0.59% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
T-Mobile US (TMUS) trades at $148.58, down 11.36% over 24 hours, reflecting recent market pressure. The stock shows strong fundamental health with revenue growth to $88.31B in 2025 and a net income margin of 11.45%. Analyst consensus is strongly bullish with a $231.10 price target, supported by a 15% dividend hike announced in September 2026. Technical indicators are mixed, with a bearish moving average signal but neutral oscillators, while recent news highlights AI-driven 5G advancements and a joint venture with AT&T and Verizon to expand coverage.
The outlook for TMUS is positive due to robust earnings beats, strategic initiatives, and solid cash flow, though risks include high debt levels and competitive pressures. Investors may find value in its growth trajectory and dividend increases, but should monitor debt management and industry competition closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
